---
title: "Cardiovascular Guidelines"
tags: [guidelines, cardiovascular]
sidebar: ccms_guidelines_sidebar
permalink: /guidelines/cardiovascular-guidelines.html
summary: Evidence-based guidelines for cardiovascular disease management
---

# Cardiovascular Guidelines

Comprehensive evidence-based guidelines for the prevention, diagnosis, and management of cardiovascular diseases.

## Primary Prevention

### Risk Assessment
- **Framingham Risk Score**: Calculate 10-year cardiovascular risk
- **ASCVD Risk Calculator**: Assess atherosclerotic cardiovascular disease risk
- **Risk Stratification**: Low (<5%), Intermediate (5-20%), High (>20%)

### Lifestyle Modifications
- **Diet**: Mediterranean diet, DASH diet, low sodium (<2.3g/day)
- **Exercise**: 150 minutes moderate or 75 minutes vigorous weekly
- **Smoking Cessation**: Complete abstinence recommended
- **Weight Management**: BMI 18.5-24.9 kg/m²

## Secondary Prevention

### Pharmacological Management
- **Antiplatelet Therapy**: Aspirin 75-100mg daily
- **ACE Inhibitors**: First-line for hypertension and heart failure
- **Beta-blockers**: Post-MI and heart failure management
- **Statins**: High-intensity statin therapy for secondary prevention

### Monitoring Parameters
- **Blood Pressure**: Target <130/80 mmHg
- **Lipid Profile**: LDL-C <70 mg/dL for high-risk patients
- **HbA1c**: <7% for diabetic patients
- **Regular Follow-up**: Every 3-6 months

## Acute Coronary Syndrome

### Initial Assessment
- **ECG**: Within 10 minutes of presentation
- **Cardiac Biomarkers**: Troponin I/T, CK-MB
- **Risk Stratification**: TIMI, GRACE, CRUSADE scores

### Management Protocol
1. **Immediate**: Aspirin 325mg, Clopidogrel 600mg loading
2. **Primary PCI**: Door-to-balloon <90 minutes
3. **Fibrinolysis**: If PCI unavailable within 120 minutes
4. **Anticoagulation**: Heparin or bivalirudin

## Heart Failure

### Classification
- **NYHA Class I-IV**: Functional capacity assessment
- **Ejection Fraction**: HFrEF (<40%), HFmrEF (40-49%), HFpEF (≥50%)

### Treatment Algorithm
- **ACE-I/ARB**: First-line therapy
- **Beta-blockers**: Carvedilol, metoprolol, bisoprolol
- **Aldosterone Antagonists**: Spironolactone, eplerenone
- **SGLT2 Inhibitors**: Dapagliflozin, empagliflozin

## References
- American Heart Association Guidelines
- European Society of Cardiology Guidelines
- ACC/AHA Clinical Practice Guidelines
